Deinove has selected key markets of interest, identified strains from its library of bacteria, which indicate suitability for commercial deployment, and formed partnerships to expedite that process. While uncertainties remain, commercial revenues are expected in 2018 and development of revenues in line with our projections would indicate a potential valuation of €4.4/share.
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Implementing the new strategy
- Published:
01 Sep 2017 -
Author:
Graeme Moyse -
Pages:
12
Deinove has selected key markets of interest, identified strains from its library of bacteria, which indicate suitability for commercial deployment, and formed partnerships to expedite that process. While uncertainties remain, commercial revenues are expected in 2018 and development of revenues in line with our projections would indicate a potential valuation of €4.4/share.